Five MPs have proposed adjusting the cost-effectiveness threshold used to evaluate new medicines in Norway's health service. The proposers argue that the threshold has not been revised since 2015, and that a recent report from the Norwegian Medicines Agency does not provide sufficient grounds to reject an adjustment, despite the report's conclusion against one. They contend that raising the threshold to reflect price growth from 2016 to 2025 would have a minimal impact on pharmaceutical budgets.
AI-generated summary · Model: Claude Haiku 4.5 · Generated: 14 May 2026
These are the proposals in the document, not decisions. See the votes for the outcome.
The Storting asks the government to promptly adjust the cost-effectiveness threshold for health services in line with price developments from 2016 to 2025.
The Storting asks the government to adjust the threshold annually for inflation based on price and productivity developments in health services, until a new revised cost benchmark reflecting Norwegian conditions has been determined.
The Storting asks the government to explain how the cost-effectiveness threshold is applied in priority-setting decisions and to consider measures that ensure better use of resources and faster patient access to effective treatments.